Physicians' Academy for Cardiovascular Education

ESC 2021

PACE-CME.org reports news from the digital ESC 2021.

Implementation of salt substitution strategies

3' education - Sep. 21, 2021 - Prof. Barbara Casadei, MD

NOAC as possible treatment option in patients with AF after successful TAVI

5' education - Sep. 13, 2021 - Prof. Nicolas van Mieghem, MD, PhD

Surgery vs. stenting with asymptomatic critical carotid artery stenosis

5' education - Sep. 7, 2021 - Prof. Freek Verheugt, MD, PhD

Non-steroidal MRA effective in reducing CV events in patients with diabetes and CKD

5' education - Aug. 31, 2021 - Prof. Bertram Pitt, MD

Switching to a salt substitute reduces risk of stroke, CV events and death

5' education - Aug. 31, 2021 - Prof. Bruce Neal, MD, PhD

Moving the field of medicine and science is a collective exercise

3' education - Aug. 29, 2021 - Prof. Stephan Achenbach, MD, president ESC

SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events

3' education - Aug. 29, 2021 - Prof. Stefan Anker, MD, PhD

Ground-breaking HF trial with evidence for SGLT2i at EF>40%

3' education - Aug. 29, 2021 - Prof. Frank Ruschitzka, MD

CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD

3' education - Aug. 28, 2021 - Kevin Damman, MD, PhD

Kidney and HF outcomes with SGLT2i across EF spectrum in HF

3' education - Aug. 28, 2021 - Prof. Rudolf de Boer, MD, PhD

What is new in the 2021 ESC HF guidelines regarding patients with EF>40%?

3' education - Aug. 27, 2021 - Prof. Carolyn Lam, MD, PhD

Exciting findings of a pooled analysis of two large HF trials with SGLT2i

3' education - Aug. 27, 2021 - Milton Packer, MD

Another chapter in the SGLT2i book

3' education - Aug. 27, 2021 - Prof. Rudolf de Boer, MD, PhD

Implementation of salt substitution strategies

3' education - Sep. 21, 2021 - Prof. Barbara Casadei, MD
Prof. Casadei gives her opinion about what we should do with the evidence from the Salt Substitute and Stroke Study (SSaSS), which showed that switching to a salt substitute reduces the risk of stroke, CV events and death.

ESC 2021 Prof. Casadei gives her opinion about what we should do with the evidence from the Salt Substitute and Stroke Study (SSaSS), which showed that switching to a salt substitute reduces the risk of stroke, CV events and death.

NOAC as possible treatment option in patients with AF after successful TAVI

5' education - Sep. 13, 2021 - Prof. Nicolas van Mieghem, MD, PhD
In the ENVISAGE-TAVI AF trial, the effect of edoxaban on net adverse clinical events (NACE)  was compared to VKAs in elderly patients with AF who underwent TAVI.

ESC 2021 In the ENVISAGE-TAVI AF trial, the effect of edoxaban on net adverse clinical events (NACE) was compared to VKAs in elderly patients with AF who underwent TAVI.

Surgery vs. stenting with asymptomatic critical carotid artery stenosis

5' education - Sep. 7, 2021 - Prof. Freek Verheugt, MD, PhD
Which procedure is better when incidentally critical carotid artery stenosis is found; carotid surgery or stenting? Prof. Verheugt discusses findings of the ACST-2 trial.

ESC 2021 Which procedure is better when incidentally critical carotid artery stenosis is found; carotid surgery or stenting? Prof. Verheugt discusses findings of the ACST-2 trial.

Starting with quarter-dose quadruple combination pill effectively lowers BP

News - Sep. 7, 2021

ESC 2021 The QUARTET trial showed that starting with a quarter-dose quadruple combination pill led to greater BP lowering compared to starting with standard dose monotherapy in patients with hypertension.

ESC debate | Do patients benefit from omega-3 fatty acids?

News - Sep. 7, 2021
Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.

ESC 2021 Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.

PCSK9 siRNA reduces LDL-c in patients with and without polyvascular disease

News - Sep. 6, 2021

ESC 2021 This pooled, post-hoc analysis of ORION-9, -10, and -11 showed that inclisiran significantly reduced LDL-c compared placebo in patients with and without polyvascular disease.

Use of lipid lowering therapy in patients at high and very high CV risk in Europe

News - Aug. 31, 2021

ESC 2021 The SANTORINI study aims to investigate whether the 2019 ESC/EAS guidelines for the management of dyslipidemia are being implemented across Europe.

Non-steroidal MRA effective in reducing CV events in patients with diabetes and CKD

5' education - Aug. 31, 2021 - Prof. Bertram Pitt, MD
Prof. Pitt shares the results of the FIGARO-DKD trial. On top of optimized RAS blockade, the non-steroidal MRA finerenone significantly reduced the risk of the composite of time to CV death, non-fatal MI, non-fatal stroke or HF hospitalization.

ESC 2021 Prof. Pitt shares the results of the FIGARO-DKD trial. On top of optimized RAS blockade, the non-steroidal MRA finerenone significantly reduced the risk of the composite of time to CV death, non-fatal MI, non-fatal stroke or HF hospitalization.

Switching to a salt substitute reduces risk of stroke, CV events and death

5' education - Aug. 31, 2021 - Prof. Bruce Neal, MD, PhD
Prof. Bruce Neal discusses the results of the SSaSS study which showed that replacing dietary salt with a salt substitute reduced stroke, CV events and death, without increasing the risk of hyperkalemia.

ESC 2021 Prof. Bruce Neal discusses the results of the SSaSS study which showed that replacing dietary salt with a salt substitute reduced stroke, CV events and death, without increasing the risk of hyperkalemia.

Each decade earlier of starting LDL-c lowering associated with stepwise increase in lifetime CV risk reduction

News - Aug. 31, 2021

ESC 2021 The Nature-PCSK9 trial, a naturally randomized target trial, showed a stepwise increase in the proportional reduction in lifetime risk of CV events with each earlier decade that LDL-c lowering was started by inhibiting PCSK9 with one-yearly dose of siRNA.

Non-inferiority criteria not met for one-month DAPT after stenting in ACS

News - Aug. 30, 2021

ESC 2021 After implantation of a stent in ACS patients, one-month DAPT followed by clopidogrel monotherapy did not demonstrate non-inferiority compared to 12-months DAPT for the net outcome of CV events and bleedings.

Stepwise approach for prevention goals in 2021 guidelines on CVD prevention

News - Aug. 30, 2021

ESC 2021 The 2021 guidelines on CVD prevention in clinical practice contain recommendations at the individual and the population level. New at the individual level is a stepwise approach to intensify preventive treatments.